Ozempic and similar medications have shown impressive results for weight loss by imitating the natural hormone GLP-1, which plays a role in regulating blood sugar and appetite. Interestingly, a new study suggests that byproducts from gut microbes might produce similar effects.
Enteroendocrine cells (EECs) in the gut are critical for generating GLP-1. Recent findings indicate that a decreased count of these cells and a drop in GLP-1 production might be contributing to obesity.
Researchers from Marshall University conducted tests on rats and lab-grown mini-guts, referred to as organoids, confirming the connection between fewer EECs and obesity. They’ve also discovered a method to boost EEC production.
“This suggests a potential therapy that could utilize gut microbes for better metabolic outcomes related to obesity,” says biochemist Alip Borthakur from the university.
The researchers turned to supplements of the amino acid tryptophan to counter the EEC deficiency. Tryptophan is already known to enhance gut health, influenced by a metabolite known as indole.
They demonstrated that tryptophan and indole could work together to create new EECs, leading to increased GLP-1 levels. Essentially, it provides a more natural alternative to achieve results similar to what one might expect from a dose of Ozempic.
Tryptophan is abundant in foods like poultry, eggs, cheese, and specific seeds. The idea is that dietary supplements or probiotics could deliver this amino acid to the gut, triggering the necessary chemical reactions.
“Our results hint that microbial metabolites from dietary tryptophan might reverse the decline in hormone-secreting gut cells associated with obesity,” Borthakur notes.
The researchers identified a specific cell receptor, the aryl hydrocarbon receptor (AhR), as part of the process—this gives them a clear target for future research.
Even though effective treatments are likely some time away, these early discoveries are quite encouraging.
Ozempic is part of a class of drugs called GLP-1 receptor antagonists, used to manage type 2 diabetes and obesity. Yet, as with many medications, side effects are a concern, highlighting the appeal of naturally boosting GLP-1 production.
This research aligns with previous studies that have explored ways to modify gut bacteria and dietary habits to enhance GLP-1 production in the body.
A next logical step will be to transition these experiments into human trials. Although lab tests provide pivotal insights, reactions in humans may differ, necessitating further exploration.
“The molecular mechanisms and signaling pathways governing EEC differentiation may vary between normal and obese conditions,” the researchers point out in their published study.
The findings were shared in the International Journal of Molecular Sciences.
